Robert Jotte, MD, PhD, discusses findings from the phase 3 KRYSTAL-12 study evaluating adagrasib in KRAS G12C-mutated NSCLC.

For Breast Cancer Awareness Month, Oranus Mohammadi, MD, discussed the remarkable progress made in improving survival rates ...

International Myeloma Society Annual Meeting was a groundbreaking event that showcased the latest advancements in multiple ...

Jeffrey Wong, MD, discusses findings on the use of Cu 64 anti-CEA M5A as a PET imaging agent for advanced rectal cancer presented at the 2024 American Society for Radiation Oncology Annual Meeting.

Acalabrutinib, a BTK inhibitor, has shown promising results in treating mantle cell lymphoma, with the FDA granting it ...

The FDA has approved nivolumab plus chemotherapy as a neoadjuvant treatment for operable stage IIA to IIIB non–small cell ...

In an interview with Targeted Oncology, Jeffrey Wong, MD, discussed the potential and future directions of Cu 64 anti-CEA M5A ...

On September 3, OBX-115, a novel TIL therapy, was granted FDA regenerative medicine advanced therapy (RMAT) designation in ...

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...

During a Case-Based Roundtable® event, Andrzej Jakubowiak, MD, PhD, surveyed how newer regimens influence a patient case of a ...

In an interview, Jeffrey Wong, MD, and Anthony Stein, MD, provided an in-depth discussion on a phase 2 trial of total marrow ...

A new combination therapy involving sonrotoclax and dexamethasone demonstrated safety, antitumor activity, and early ...